Epstein–Barr virus LMP1 protein promotes proliferation and inhibits differentiation of epithelial cells via activation of YAP and TAZ
Proceedings of the National Academy of Sciences · 16.05.2023 · 120 (20)
DOI: 10.1073/pnas.2219755120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 08.05.2023. Verfasst von Deo R Singh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Wisconsin School of Medicine and Public Health, WIMR II, Madison, WI 53705. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
Latent Epstein–Barr virus (EBV) infection promotes undifferentiated nasopharyngeal carcinomas (NPCs) in humans, but the mechanism(s) for this effect has been difficult to study because EBV cannot transform normal epithelial cells in vitro and the EBV genome is often lost when NPC cells are grown in culture. Here we show that the latent EBV protein, LMP1 (Latent membrane protein 1), induces cellular proliferation and inhibits spontaneous differentiation of telomerase-immortalized normal oral keratinocytes (NOKs) in growth factor-deficient conditions by increasing the activity of the Hippo pathway effectors, YAP (Yes-associated protein) and TAZ (Transcriptional coactivator with PDZ-binding motif). We demonstrate that LMP1 enhances YAP and TAZ activity in NOKs both by decreasing Hippo pathway-mediated serine phosphorylation of YAP and TAZ and increasing Src kinase-mediated Y357 phosphorylation of YAP. Furthermore, knockdown of YAP and TAZ is sufficient to reduce proliferation and promote differentiation in EBV-infected NOKs. We find that YAP and TAZ are also required for LMP1-induced epithelial-to-mesenchymal transition. Importantly, we demonstrate that ibrutinib (an FDA-approved BTK inhibitor that blocks YAP and TAZ activity through an off-target effect) restores spontaneous differentiation and inhibits proliferation of EBV-infected NOKs at clinically relevant doses. These results suggest that LMP1-induced YAP and TAZ activity contributes to the development of NPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, University of Wisconsin School of Medicine and Public Health, WIMR II, Madison, WI 53705.
- Department of Medicine, University of Wisconsin School of Medicine and Public Health, WIMR II, Madison, WI 53705.
ORCID-Profile: Deo R Singh, Scott E Nelson, Alisha S Kansra, Jillian A Bristol
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- HHS | National Institutes of Health
Zitieren
APA
Singh, D. R., Nelson, S. E., Pawelski, A. S., Kansra, A. S., Fogarty, S. A., Bristol, J. A., Ohashi, M., Johannsen, E. C., & Kenney, S. C. (2023). Epstein–Barr virus LMP1 protein promotes proliferation and inhibits differentiation of epithelial cells via activation of YAP and TAZ. Proceedings of the National Academy of Sciences, 120(20). https://doi.org/10.1073/pnas.2219755120
Vancouver
Singh DR, Nelson SE, Pawelski AS, Kansra AS, Fogarty SA, Bristol JA, et al. Epstein–Barr virus LMP1 protein promotes proliferation and inhibits differentiation of epithelial cells via activation of YAP and TAZ. Proceedings of the National Academy of Sciences. 2023;120(20). doi:10.1073/pnas.2219755120
BibTeX
@article{Singh2023,
author = {Singh, Deo R and Nelson, Scott E and Pawelski, Abigail S and Kansra, Alisha S and Fogarty, Stuart A and Bristol, Jillian A and Ohashi, Makoto and Johannsen, Eric C and Kenney, Shannon C},
title = {Epstein–Barr virus LMP1 protein promotes proliferation and inhibits differentiation of epithelial cells via activation of YAP and TAZ},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
volume = {120},
number = {20},
doi = {10.1073/pnas.2219755120}
}
EUVIMED